RetaMaps Editorial· Updated October 2, 2026· Editorial review · Medical review pending
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Short answer: no. The FDA has said it directly: "Retatrutide and
cagrilintide cannot be used in compounding under federal law." [1]
Why semaglutide was different
The compounded-GLP-1 market most people know came from a specific legal
mechanism: when an FDA-approved drug is in a declared shortage,
compounding pharmacies may prepare versions of it under defined conditions.
Semaglutide and tirzepatide went through declared shortages, and a large
compounding market grew in that window.
Retatrutide never qualifies for that mechanism, because the mechanism starts
with an approved drug. Retatrutide is investigational — not approved, no
commercial supply, available only in clinical trials and Lilly's
expanded access program. [2] There is no shortage of a product
that doesn't exist, and no lawful compounding pathway for it.
What "compounded retatrutide" actually is
Anything sold or administered as compounded retatrutide is an unapproved drug
from an unregulated source — functionally the same gray market as
"research peptide" vials, sometimes literally the same suppliers
with different packaging. The enforcement record reflects that: FDA warning
letters to sellers using code names like "GLP-1-R" [4],
and Lilly's August 2026 lawsuits against six U.S. defendants — including
a compounding pharmacy and a med spa. [3]
Red flags, in practice
A clinic or website offering retatrutide in any form today — injection,
"compounded," oral drops, pellets.
If a provider listed on RetaMaps does any of the above,
report the listing — our compliance screening removes
practices that sell or refer patients to illicit retatrutide.
The legitimate paths
Clinical trials, Lilly's
expanded access program (your physician
applies and medical criteria must be met), or FDA-approved GLP-1 medications
prescribed today by a licensed clinician.
But I got compounded semaglutide — why is this different?
Compounded semaglutide was possible during an FDA-declared shortage of an approved drug. Retatrutide isn't an approved drug at all, so the shortage pathway never applies to it. The FDA's position: retatrutide and cagrilintide cannot be used in compounding under federal law.
A med spa near me offers 'compounded reta.' Is that a real pharmacy product?
No. Whatever they're administering, it isn't a lawful compounded version of retatrutide — none exists. One of the defendants in Lilly's August 2026 lawsuits was a med spa.
Will compounded retatrutide become legal after FDA approval?
Only under narrow conditions that apply to approved drugs (like a declared shortage), and that's entirely hypothetical until approval happens. Today the answer is simply no.
Find weight-loss providers near you
Browse the practices RetaMaps tracks, or get an email when retatrutide's status changes.
